Cantor Fitzgerald reiterates Freshworks stock rating at Overweight By Investing.com

Freshworks reported Q1 2026 revenue of $228.6 million, up 16% year over year, with operating margin at 18% and gross margin at 85%. Management raised full-year guidance by about $5 million, but also cut 2026 customer experience ARR growth expectations from mid-single digits to low-single digits, tempering the beat. Cantor Fitzgerald kept an Overweight rating with a $12 target, while Needham reiterated Buy at $15.

Analysis

FRSH is in the awkward part of a rerating cycle where the stock can still grind higher on fundamentals, but not cleanly enough to attract momentum capital. The key issue is not the quarter itself; it is that management is signaling a slower terminal growth profile in the legacy CX franchise while the market still wants evidence that the re-platforming will expand, not dilute, the long-term opportunity set. That creates a valuation trap: a “cheap” multiple can stay cheap if investors believe the company is trading near a structurally lower growth regime.

The more interesting second-order effect is competitive. As Freshworks deemphasizes lower-quality SMB tail demand, it may improve near-term sales efficiency and gross retention optics, but it also risks ceding share in the long tail to point solutions and broader IT workflow vendors that can bundle aggressively. Over the next 2-3 quarters, the market will likely treat Device42 integration as the litmus test: if cross-sell does not offset the CX slowdown, the mix shift becomes a margin story rather than a growth story.

The setup is mildly bullish only if the market is underestimating how much of the current guidance debate is about normalization in FX and product transition rather than demand deterioration. But the upside case still needs proof in bookings, not revenue, because management’s tone suggests the sell-side may be modeling too much operating leverage too early. If enterprise expansion from Device42 accelerates, the stock can rerate quickly; if not, this is a dead-money compounder until at least the next 1-2 prints.

Contrarian take: consensus is probably overfocusing on the headline undervaluation screens and underweighting the fact that the company just telegraphed a lower-growth core segment. In software, guidance confidence matters as much as growth rate, and any perception that management is “managing expectations” around FX or segment mix can cap multiple expansion even with decent execution.

Key Decisions for Investors

• Maintain a tactical long only on weakness: buy FRSH on a 5-8% post-earnings pullback, targeting a 15-20% rebound over 1-2 quarters if Device42 cross-sell shows up in bookings; stop out if next-quarter ARR growth fails to stabilize.
• Use a call spread rather than outright stock: FRSH 3-6 month 10/15 call spread to capture rerating upside while limiting downside if the market keeps pricing a slower CX trajectory.
• Pair trade: long FRSH / short a slower-growing SMB-exposed software name with weaker execution visibility over the next 2 quarters; the relative value works only if Freshworks proves mix improvement without sacrificing bookings.
• If holding existing FRSH, trim on any move into the low-teens until management demonstrates at least one quarter of sequential improvement in customer experience ARR and net new enterprise contribution.